SOST and nasopharyngitis: Dongye Zhang et al. used the sclerostin antibody to retain osteocytic micromorphology and function to rescue bone mass against prolonged mechanical unloading (Zhang et al., 2017; Zhang et al., 2020), while a phase 3 trial reported that patients administered with romosozumab (sclerostin monoclonal antibody) may experience some adverse events, such as nasopharyngitis, arthralgia, and hypercalcemia (Langdahl et al., 2017).